Location History:
- Toulouse, FR (2019)
- Mauressac, FR (2016 - 2021)
Company Filing History:
2 out of 1,744 
2 out of 2 
1 out of 1 
Years Active: 2016-2021
Title: **Olivier Dubreuil: Innovator in Therapeutic Antibodies**
Introduction
Olivier Dubreuil is a prominent inventor located in Mauressac, France, with a focus on developing innovative therapeutic antibodies. He holds three patents that highlight his significant contributions to the field of biomedicine.
Latest Patents
Olivier's latest patents include pioneering work on anti-human-HER3 antibodies. This particular patent describes a neuregulin non-competitive allosteric anti-human-HER3 antibody characterized by a human constant region. Notably, less than 65% of the glycan structures at the glycosylation site of this antibody contain a fucose molecule, showcasing its unique variable sequences.
Additionally, he has developed innovative antibody drug conjugates (ADCs) and antibody conjugates (ACs). This invention specifically targets the human anti-Müllerian hormone type II receptor (AMHR-II) and can be employed to diagnose and treat various cancers, including prostate cancer, breast cancer, and gynecologic cancers like metastatic ovarian cancer. His work could significantly impact the treatment landscape for conditions expressed by AMHR-II.
Career Highlights
Throughout his career, Olivier has contributed meaningfully to biotechnology, particularly in the development of antibody therapies. His role in Gamamabs Pharma, both at Gamamabs Pharma Sa and Gamamabs Pharma, has allowed him to leverage his expertise in antibody innovation.
Collaborations
Olivier has worked alongside notable colleagues, such as Christel Larbouret and Jean-François Prost. These collaborations have bolstered his research and development efforts, facilitating advancements in therapeutic approaches utilizing antibodies.
Conclusion
Olivier Dubreuil exemplifies innovation in the field of therapeutic antibodies. His patents reflect a commitment to advancing medical science and improving treatment options for patients with challenging cancers. As he continues to contribute to the scientific community, Olivier's work is anticipated to have a lasting impact on biomedicine.